There's little point in pouring hundreds of millions of dollars into creating a biosimilar if PBMs will refuse to cover it.

A new FTC report claims that pharmacy benefit managers generated $7.3bn by marking up specialty generics used to treat diseases like cancer and HIV.

The FTC's long-awaited report on pharmacy benefit managers is out, and makes uncomfortable reading for the pharma supply chain middlemen.

Health Secretary Robert F. Kennedy Jr. looks poised to win the battle over fluoride, to the dismay of dentists and oral ...

Just before President Trump pushed her out at the behest of his corporate donors, former Federal Trade Commission chairwoman Lina Khan released a damning report about the most rapacious and ...

In a letter, obtained first by Spectrum News NY1, the Democrats are urging a House Appropriations subcommittee to insert language in an upcoming budget bill.

Bil Schmidtknecht blames pharmacy benefit managers for the death of his son. He won’t rest until he holds them accountable.

A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for ...